The significance of dynamin 2 expression for prostate cancer progression, prognostication, and therapeutic targeting. (18th December 2013)

• Record Type: Journal Article
• Authors: Xu, Bin; Teng, Liang Hong; Silva, Sabrina Daniela da; Bijian, Krikor; Al Bashir, Samir; Jie, Su; Dolph, Michael; Alaoui‐Jamali, Moulay A.; Bismar, Tarek A.
• Is Part Of: Cancer medicine. Volume 3:Number 1(2014:Feb.)
• Page Start: 14
• Page End: 24
• Publication Date: 2013-12-18
• Subjects: Cancer‐specific mortality -- castration resistance -- dynamin -- prostate cancer -- therapeutic target; 616.994005
• DOI: 10.1002/cam4.168
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Dynamin 2 (Dyn2) is essential for intracellular vesicle formation and trafficking, cytokinesis, and receptor endocytosis. In this study, we investigated the implication of Dyn2 as a prognostic marker and therapeutic target for progressive prostate cancer (PCA). We evaluated Dyn2 protein expression by immunohistochemistry in two cohorts: men with localized PCA treated by retropubic radical prostatectomy ( n = 226), and men with advanced/castrate‐resistant PCA (CRPC) treated by transurethral resection of prostate (TURP) ( n = 253). The role of Dyn2 in cell invasiveness was assessed by in vitro and in vivo experiments using androgen‐responsive and refractory PCA preclinical models. Dyn2 expression was significantly increased across advanced stages of PCA compared to benign prostate tissue ( P < 0.0001). In the CRPC cohort, high Dyn2 was associated with higher Gleason score ( P = 0.004) and marginally with cancer‐specific mortality ( P = 0.052). In preclinical models, Dyn2 gene silencing significantly reduced cell migration and invasion in vitro, as well as tumor size and lymph node metastases in vivo. In isolated PCA cells, Dyn2 was found to regulate focal adhesion turnover, which is critical for cell migration; this mechanism requires full Dyn2 compared to mutants deficient in GTPase activity. In conclusion, Dyn2 overexpression is associated with neoplastic prostate epithelium and is associated with poor prognosis. Inhibition of Dyn2 prevents cell invasiveness in androgen‐responsive and ‐refractory PCA models, supporting the potential benefit of Dyn2 to serve as a therapeutic target for advanced PCA. Abstract : Dynamin 2 (Dyn 2) overexpression is a predictive marker for prostate cancer (PCA) progression and poor prognosis. Dyn2 inhibition prevents cell invasiveness in androgen‐responsive and androgen‐refractory PCA models, which support the potential of Dyn2 to serve as a therapeutic target for advanced PCA.